Semin Thromb Hemost 2019; 45(04): 342-347
DOI: 10.1055/s-0039-1687890
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Disseminated Intravascular Coagulation in Cancer: An Update

Marcel Levi
1   Department of Medicine, University College London Hospitals, London, United Kingdom
2   Biomedical Research Centre, University College London Hospitals, London, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
30 April 2019 (online)

Abstract

Cancer often leads to the activation of coagulation, manifesting as disseminated intravascular coagulation (DIC) in its most extreme form. DIC is characterized by systemic intravascular coagulation activation (leading to deposition of intravascular platelets and fibrin) and simultaneous consumption of coagulation proteins and thrombocytes (which may cause bleeding complications). The clinical course of DIC in patients with malignancies is typically less intense compared with DIC complicating alternative clinical settings, including systemic inflammatory responses following infection or traumatic injury. A more slowly proceeding, less fulminant, and widespread hemostatic derangement can remain asymptomatic. Eventually, the ongoing consumption may result in low levels of platelets and coagulation factors, and bleeding complications (frequently localized at the site of the tumor or distant metastases) may be the first clinical manifestation of DIC. An alternative clinical scenario is dominated by thrombotic complications, ranging from clinically manifest vascular thrombosis to microvascular platelet plugs. The main principle of DIC management is adequate treatment of the precipitating disorder; however, there are clinical presentations that may require additional supportive strategies specifically aimed at the amelioration of the coagulopathy.

 
  • References

  • 1 Levi M. Cancer-related coagulopathies. Thromb Res 2014; 133 (Suppl. 02) S70-S75
  • 2 Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol 2009; 22 (01) 129-136
  • 3 Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res 2001; 102 (06) V187-V194
  • 4 Levi M. Cancer and thrombosis. Clin Adv Hematol Oncol 2003; 1 (11) 668-671
  • 5 Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001; 86 (03) 828-833
  • 6 Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 2001; 27 (06) 593-604
  • 7 Sarris AH, Kempin S, Berman E. , et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992; 79 (05) 1305-1310
  • 8 Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70 (01) 43-48
  • 9 Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis 1998; 28 (Suppl. 03) 50-60
  • 10 Libourel EJ, Klerk CPW, van Norden Y. , et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood 2016; 128 (14) 1854-1861
  • 11 Feinstein DI. Disseminated intravascular coagulation in patients with solid tumors. Oncology (Williston Park) 2015; 29 (02) 96-102
  • 12 Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Haematol 2001; 106 (1-2): 52-56
  • 13 Levi M. Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. Thromb Res 2018; 164 (Suppl. 01) S77-S81
  • 14 Donati MB. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74 (01) 278-281
  • 15 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease [see comments]. Nat Med 1996; 2 (02) 209-215
  • 16 Rickles FR, Brenner B. Tissue factor and cancer. Semin Thromb Hemost 2008; 34 (02) 143-145
  • 17 Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A 1995; 92 (18) 8205-8209
  • 18 Zhang Y, Deng Y, Luther T. , et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94 (03) 1320-1327
  • 19 Nadir Y, Vlodavsky I, Brenner B. Heparanase, tissue factor, and cancer. Semin Thromb Hemost 2008; 34 (02) 187-194
  • 20 Milsom C, Yu J, May L, Magnus N, Rak J. Diverse roles of tissue factor-expressing cell subsets in tumor progression. Semin Thromb Hemost 2008; 34 (02) 170-181
  • 21 Hyman DM, Soff GA, Kampel LJ. Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature. Oncology 2011; 81 (02) 119-125
  • 22 Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009; 148: 43-66
  • 23 Tallman MS. The thrombophilic state in acute promyelocytic leukemia. Semin Thromb Hemost 1999; 25 (02) 209-215
  • 24 Rodeghiero F, Castaman G. The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. Leukemia 1994; 8 (Suppl. 02) S20-S26
  • 25 Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009; 22 (01) 153-163
  • 26 Mitrovic M, Suvajdzic N, Elezovic I. , et al. Thrombotic events in acute promyelocytic leukemia. Thromb Res 2015; 135 (04) 588-593
  • 27 Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 2015; 66 (05) 857-868
  • 28 Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992; 19 (05) 580-596
  • 29 Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14 (04) 495-504
  • 30 Snyder Jr HW, Mittelman A, Oral A. , et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 1993; 71 (05) 1882-1892
  • 31 Guinan EC, Tarbell NJ, Niemeyer CM, Sallan SE, Weinstein HJ. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1988; 72 (02) 451-455
  • 32 Antignac C, Gubler MC, Leverger G, Broyer M, Habib R. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 1989; 35 (06) 1336-1344
  • 33 Rabinowe SN, Soiffer RJ, Tarbell NJ. , et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991; 77 (08) 1837-1844
  • 34 Levi M, Scully M, Singer M. The role of ADAMTS-13 in the coagulopathy of sepsis. J Thromb Haemost 2018; 16 (04) 646-651
  • 35 Jackson AM, Rose BD, Graff LG. , et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101 (01) 41-44
  • 36 Garcia G, Atallah JP. Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract 2017; 23 (02) 135-142
  • 37 Chappell ME, Keeling DM, Prentice HG, Sweny P. Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?. Bone Marrow Transplant 1988; 3 (04) 339-347
  • 38 Holler E, Kolb HJ, Hiller E. , et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989; 73 (07) 2018-2024
  • 39 Collins PW, Gutteridge CN, O'Driscoll A. , et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 1992; 10 (06) 499-506
  • 40 Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007; 33 (08) 787-797
  • 41 Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 1990; 8 (06) 511-518
  • 42 Conway EM, Van de Wouwer M, Pollefeyt S. , et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196 (05) 565-577
  • 43 Levi M, ten Cate JW, Dooijewaard G, Sturk A, Brommer EJ, Agnelli G. DDAVP induces systemic release of urokinase-type plasminogen activator. Thromb Haemost 1989; 62 (02) 686-689
  • 44 Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 1980; 43 (02) 77-89
  • 45 Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27 (01) 3-9
  • 46 Wada H, Kaneko T, Ohiwa M. , et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 1993; 44 (02) 101-105
  • 47 Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002; 30 (5, Suppl): S220-S224
  • 48 Straub PW. Diffuse intravascular coagulation in liver disease?. Semin Thromb Hemost 1977; 4 (01) 29-39
  • 49 Levi M. Disseminated intravascular coagulation: a disease-specific approach. Semin Thromb Hemost 2010; 36 (04) 363-365
  • 50 Seligsohn U. Disseminated intravascular coagulation. In: Handin RI, Lux SE, Stossel TP. , eds. Blood: Principles and Practice of Hematology. Philadelphia, PA: J.B. Lippincott; 2000
  • 51 Sack Jr GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56 (01) 1-37
  • 52 Lopez JA, Ross RS, Fishbein MC, Siegel RJ. Nonbacterial thrombotic endocarditis: a review. Am Heart J 1987; 113 (03) 773-784
  • 53 Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood 2018; 131 (08) 845-854
  • 54 Wada H, Thachil J, Di Nisio M. , et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013 (e-pub ahead of print). doi:10.1111/jth.12155
  • 55 Thachil J, Falanga A, Levi M, Liebman H, Di Nisio M. ; Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. J Thromb Haemost 2015; 13 (04) 671-675
  • 56 Levi M. Management of cancer-associated disseminated intravascular coagulation. Thromb Res 2016; 140 (Suppl. 01) S66-S70
  • 57 Martí-Carvajal AJ, Anand V, Solà I. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database Syst Rev 2015; (06) CD008562
  • 58 Thachil J, Falanga A, Levi M, Liebman H, Di NM. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. Reply J Thromb Haemost 2015; 13 (04) 671-675
  • 59 Kakkar AK, Kadziola Z, Williamson RC. Low molecular weight heparin therapy and survival in advanced cancer. Blood 2002; 100: 148a
  • 60 Schünemann HJ, Ventresca M, Crowther M. , et al; IPDMA heparin use in cancer patients research group. Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open 2016; 6 (04) e010569
  • 61 Di Minno MND, Ageno W, Lupoli R. , et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. Eur Respir J 2017; 50 (03) 1701097
  • 62 Cook DJ, Crowther MA, Meade MO, Douketis J. ; VTE in the ICU Workshop Participants. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care 2005; 20 (04) 309-313
  • 63 Patel R, Cook DJ, Meade MO. , et al; Burden of Illness in venous ThromboEmbolism in Critical care (BITEC) Study Investigators; Canadian Critical Care Trials Group. Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care 2005; 20 (04) 341-347
  • 64 Niers TM, Klerk CP, DiNisio M. , et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007; 61 (03) 195-207
  • 65 Corrigan Jr JJ, Jordan CM. Heparin therapy in septicemia with disseminated intravascular coagulation. N Engl J Med 1970; 283 (15) 778-782
  • 66 Audibert G, Lambert H, Toulemonde F. , et al. Use of a low molecular weight heparin, CY 222, in the treatment of consumption coagulopathy [in French]. J Mal Vasc 1987; 12 (Suppl B): 147-151
  • 67 Feinstein DI. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost 1988; 14 (04) 351-362
  • 68 Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006; 10 (04) 222
  • 69 Saito H, Maruyama I, Shimazaki S. , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5 (01) 31-41
  • 70 Matsushita T, Watanabe J, Honda G. , et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res 2014; 133 (05) 772-781
  • 71 Yokoyama H, Takahashi N, Katsuoka Y. , et al; Tohoku Hematology Forum. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum. Int J Hematol 2017; 105 (05) 606-613
  • 72 Asakura H, Takahashi H, Tsuji H. , et al. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy. Thromb Res 2014; 133 (03) 364-370
  • 73 Tamura K, Saito H, Asakura H. , et al. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial. Int J Clin Oncol 2015; 20 (04) 821-828
  • 74 Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356 (22) 2301-2311
  • 75 Wheater MJ, Mead GM, Bhandari S, Fennell J. Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma. J Clin Oncol 2008; 26 (06) 1008-1010
  • 76 Shenoy A, Savani BN, Barrett AJ. Recombinant factor VIIa to treat diffuse alveolar hemorrhage following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13 (05) 622-623
  • 77 Erikci AA, Ozturk A, Sayan O. Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia. Blood Coagul Fibrinolysis 2006; 17 (04) 323-324